Integrating SEND outcomes in IND-enabling studies

SEND (Standard for Exchange of Nonclinical Data) describes a structured way to submit nonclinical data in a consistent format to U.S. Food and Drug Administration (FDA). SEND aims to improve the efficiency and quality of the Investigative New Drug (IND) and New Drug Application (NDA) processes.

SEND submission is now mandatory for single dose toxicity, repeat-dose toxicity, carcinogenicity, cardiovascular and respiratory studies. However, the flexible interpretation of these guidelines and resulting variability in the output datasets¹ can cause delays and inefficiencies in the review process.

As an industry partner with deep expertise in IND-enabling studies, emka TECHNOLOGIES helps nonclinical scientists comply with SEND requirements by generating SEND 3.1 compatible tables directly from emka TECHNOLOGIES software.

The data can easily be exported to .xls, .csv and integrated into third-party solutions by Instem and Xybion to increase productivity in preclinical studies.

Main features

Selection of SEND variables for each domain
Semi-automatic population of the domains wherever possible.
Choice lists available with the full CDISC terminology
Management of the format codes from the implementation guide
Preview SEND-formatted data ready to be exported as .xls or .csv files
No need to re-validate your acquisition system. SEND export module works with any
IOX version.

References

Empowering researchers

Welcome to emka’s knowledge center. You can find everything you need to get most out of your emka TECHNOLOGIES system.

Publications

Resources

Researcher spotlight

Insights